UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March ~~February 3~~30, 2026

Lipella Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41575		20-2388040
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

7800 Susquehanna St., Suite 505

Pittsburgh, PA

15208

(Address of registrant’s principal executive office)

(Zip code)

Registrant’s telephone number, including area code: (412) 894-1853

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5 1.0203 ~~Departure~~Bankruptcy ~~of Directors~~ or ~~Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.~~Receivership

On ~~February~~ 3,[Filing ~~2026~~Date], ~~Lori~~[Company ~~A. Birder notified Lipella Pharmaceuticals~~ Name, Inc.] (the “Company”) and certain of ~~her~~its ~~resignation~~subsidiaries ~~from~~(collectively, the ~~Company’s Board~~“Debtors”) offiled ~~Directors,~~voluntary petitions ~~effective~~for ~~immediately.~~relief ~~Dr.~~under ~~Birder’s~~Chapter ~~decision~~11 toof ~~resign~~Title ~~was~~11 ~~not~~of ~~due~~the toUnited ~~any~~States ~~disagreement~~Code ~~with~~in the ~~Company~~United ~~on any~~States ~~matter~~Bankruptcy ~~relating~~Court tofor ~~its~~the Western ~~operations,~~District ~~policies~~of orPennsylvania ~~practices~~(the “Bankruptcy Court”).

~~SIGNATURES~~Cautionary Note Regarding Chapter 11 Case

~~Pursuant~~The Company cautions that trading in the toCompany’s common stock during the ~~requirements~~pendency of the ~~Securities~~Chapter ~~Exchange~~11 ~~Act~~case ofis ~~1934,~~highly speculative and poses substantial risks. Trading prices for the ~~registrant~~Company’s ~~has~~common ~~duly~~stock ~~caused~~may ~~this~~bear ~~report~~little or no relationship to bethe ~~signed~~actual onrecovery, ~~its~~if ~~behalf~~any, by holders of the Company’s ~~undersigned~~common ~~hereunto~~stock ~~duly~~in ~~authorized~~the Chapter 11 Cases.

Date: February 4, 2026	Lipella Pharmaceuticals Inc.
	By:	/s/ Jonathan Kaufman
		Name: Jonathan Kaufman Title: Chief Executive Officer

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated March 30, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 30, 2026	Lipella Pharmaceuticals Inc.

	By:	/s/ Jonathan Kaufman
		Name: Jonathan Kaufman Title: Chief Executive Officer

Filing Compare · LIPELLA PHARMACEUTICALS INC.